← All trials
NCT04645069
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 20, 2020
- Primary completion
- Nov 16, 2022
- Completion date
- Apr 16, 2023
- First posted
- Nov 27, 2020
- Last posted
- Nov 27, 2020
- Enrollment
- 100
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Adagene IncLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.